Choose your preferred way to stay informed of new case launches and settlement deadlines
Zentalis announced on June 18, 2024, that "the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC)." Following this news, Zentalis's stock price fell over 50% on June 18, 2024.
In order to be eligible to join the ZNTL class action lawsuit, you must have incurred a loss on shares of Zentalis purchased during the class period listed above.
TOP
